Compare Knight Therapeutics, Inc. with Similar Stocks
Dashboard
1
With a growth in Net Sales of 13.01%, the company declared Very Positive results in Jun 26
- The company has declared positive results for the last 2 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at CAD 112.9 MM
- NET SALES(HY) At CAD 292.65 MM has Grown at 49.74%
- ROCE(HY) Highest at 1.9%
2
With ROE of 1.37%, it has a expensive valuation with a 1.16 Price to Book Value
3
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CAD 986 Million (Small Cap)
85.00
NA
0.00%
-0.10
3.00%
1.24
Revenue and Profits:
Net Sales:
144 Million
(Quarterly Results - Jun 2026)
Net Profit:
-3 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.53%
0%
10.53%
6 Months
60.53%
0%
60.53%
1 Year
66.5%
0%
66.5%
2 Years
70.93%
0%
70.93%
3 Years
132.28%
0%
132.28%
4 Years
90.2%
0%
90.2%
5 Years
97.5%
0%
97.5%
Knight Therapeutics, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
20.64%
EBIT Growth (5y)
22.85%
EBIT to Interest (avg)
-0.14
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.11
Sales to Capital Employed (avg)
0.48
Tax Ratio
30.46%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.15%
ROCE (avg)
0.98%
ROE (avg)
1.02%
Valuation key factors
Factor
Value
P/E Ratio
85
Industry P/E
Price to Book Value
1.16
EV to EBIT
61.87
EV to EBITDA
11.36
EV to Capital Employed
1.18
EV to Sales
1.67
PEG Ratio
0.66
Dividend Yield
NA
ROCE (Latest)
1.91%
ROE (Latest)
1.37%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
Shareholding Snapshot : Dec 2023
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.15%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
144.20
148.40
-2.83%
Operating Profit (PBDIT) excl Other Income
24.00
26.80
-10.45%
Interest
2.10
2.60
-19.23%
Exceptional Items
-9.70
-2.00
-385.00%
Consolidate Net Profit
-3.40
13.20
-125.76%
Operating Profit Margin (Excl OI)
62.10%
71.30%
-0.92%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is -2.83% vs 11.50% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is -125.76% vs 48.31% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
450.10
371.30
21.22%
Operating Profit (PBDIT) excl Other Income
54.40
60.60
-10.23%
Interest
10.40
9.20
13.04%
Exceptional Items
-2.50
-11.60
78.45%
Consolidate Net Profit
-5.40
4.30
-225.58%
Operating Profit Margin (Excl OI)
-4.90%
20.20%
-2.51%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 21.22% vs 13.13% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -225.58% vs 125.60% in Dec 2024
About Knight Therapeutics, Inc. 
Knight Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Knight Therapeutics Inc is a Canada-based specialty pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices. The Company’s products are ILUVIEN Fluocinolone acentonid, Nerlynx Neratinib Tablets, Burinex Bumetanide, Probuphine Buprenorphine implant and Movantik Naloxegol.
Company Coordinates 
Company Details
3400 De Maisonneuve Blvd W , MONTREAL QC : H3Z 3B8
Registrar Details






